Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
1.
Front Biosci (Landmark Ed) ; 27(9): 253, 2022 08 31.
Artigo em Inglês | MEDLINE | ID: covidwho-2067594

RESUMO

SIRT1 was discovered in 1979 but growing interest in this protein occurred only 20 years later when its overexpression was reported to prolong the lifespan of yeast. Since then, several studies have shown the benefits of its increased expression in preventing or delaying of many diseases. SIRT1, as a histone deacetylase, is an epigenetic regulator but it has wide range of non-histone targets which are involved in metabolism, energy sensing pathways, circadian machinery and in inflammatory regulation. Disturbances in these interconnected processes cause different diseases, however it seems they have common roots in unbalanced inflammatory processes and lower level or inactivation of SIRT1. SIRT1 inactivation was implicated in coronavirus disease (COVID-19) severity as well and its low level counted as a predictor of uncontrolled COVID-19. Several other diseases such as metabolic disease, obesity, diabetes, Alzheimer's disease, cardiovascular disease or depression are related to chronic inflammation and similarly show decreased SIRT1 level. It has recently been known that SIRT1 is inducible by calorie restriction/proper diet, physical activity and appropriate emotional state. Indeed, a healthier metabolic state belongs to higher level of SIRT1 expression. These suggest that appropriate lifestyle as non-pharmacological treatment may be a beneficial tool in the prevention of inflammation or metabolic disturbance-related diseases as well as could be a part of the complementary therapy in medical practice to reach better therapeutic response and quality of life. We aimed in this review to link the beneficial effect of SIRT1 with those diseases, where its level decreased. Moreover, we aimed to collect evidences of interventions or treatments, which increase SIRT1 expression and thus, open the possibility to use them as preventive or complementary therapies in medical practice.


Assuntos
Epigênese Genética , Doenças Metabólicas , Neoplasias , Sirtuína 1 , COVID-19 , Homeostase , Humanos , Inflamação , Doenças Metabólicas/genética , Doenças Metabólicas/prevenção & controle , Neoplasias/genética , Neoplasias/prevenção & controle , Qualidade de Vida , Sirtuína 1/genética , Sirtuína 1/metabolismo
2.
Nutrients ; 13(8)2021 Aug 01.
Artigo em Inglês | MEDLINE | ID: covidwho-1379982

RESUMO

The Mediterranean diet (MD) has been considered among the healthiest dietary patterns since a little over 50 years ago, Ancel Keys-as the key figure-provided evidence for the beneficial effects of the MD [...].


Assuntos
Dieta Saudável/métodos , Dieta Mediterrânea , Doenças Metabólicas/dietoterapia , Doenças Metabólicas/prevenção & controle , Dieta Saudável/tendências , Humanos
3.
Front Endocrinol (Lausanne) ; 12: 649405, 2021.
Artigo em Inglês | MEDLINE | ID: covidwho-1295631

RESUMO

The finding that high-dose dexamethasone improves survival in those requiring critical care due to COVID-19 will mean much greater usage of glucocorticoids in the subsequent waves of coronavirus infection. Furthermore, the consistent finding of adverse outcomes from COVID-19 in individuals with obesity, hypertension and diabetes has focussed attention on the metabolic dysfunction that may arise with critical illness. The SARS coronavirus itself may promote relative insulin deficiency, ketogenesis and hyperglycaemia in susceptible individuals. In conjunction with prolonged critical care, these components will promote a catabolic state. Insulin infusion is the mainstay of therapy for treatment of hyperglycaemia in acute illness but what is the effect of insulin on the admixture of glucocorticoids and COVID-19? This article reviews the evidence for the effect of insulin on clinical outcomes and intermediary metabolism in critical illness.


Assuntos
Tratamento Farmacológico da COVID-19 , Glucocorticoides/efeitos adversos , Insulina/uso terapêutico , Doenças Metabólicas/induzido quimicamente , Doenças Metabólicas/prevenção & controle , COVID-19/complicações , Cuidados Críticos/métodos , Estado Terminal/terapia , Dexametasona/efeitos adversos , Dexametasona/uso terapêutico , Complicações do Diabetes/diagnóstico , Complicações do Diabetes/tratamento farmacológico , Complicações do Diabetes/mortalidade , Diabetes Mellitus/tratamento farmacológico , Diabetes Mellitus/mortalidade , Diabetes Mellitus/virologia , Glucocorticoides/uso terapêutico , Humanos , Hiperglicemia/complicações , Hiperglicemia/tratamento farmacológico , Hiperglicemia/mortalidade , Doenças Metabólicas/etiologia , Obesidade/complicações , Obesidade/tratamento farmacológico , Obesidade/mortalidade , SARS-CoV-2/fisiologia , Resultado do Tratamento
4.
Med Hypotheses ; 146: 110416, 2021 Jan.
Artigo em Inglês | MEDLINE | ID: covidwho-970166

RESUMO

The COVID-19 pandemic has placed significant restrictions on people's daily activities and even change their eating habits, yet it has inadvertently allowed people to benefit potentially from this restriction for certain diseases. The COVID-19 outbreak has had the positive effect of changing the nutritional status of some populations. From this point of view, the COVID-19 pandemic is cleverly beneficial.


Assuntos
COVID-19/epidemiologia , Estilo de Vida , Doenças Metabólicas/prevenção & controle , Pandemias , SARS-CoV-2 , COVID-19/psicologia , China/epidemiologia , Exercício Físico , Comportamento Alimentar , Humanos , Incidência , Doenças Metabólicas/epidemiologia , Estado Nutricional , Fatores de Risco
5.
J Pediatr Endocrinol Metab ; 34(1): 103-107, 2021 Jan 27.
Artigo em Inglês | MEDLINE | ID: covidwho-947985

RESUMO

OBJECTIVES: There has been a recent worldwide outbreak of coronavirus disease (COVID-19). Most of the health system capacity has been directed to COVID-19 patients, and routine outpatient clinics have been suspended. Chronic disease patients, such as inherited metabolic disorders (IMD), have had trouble accessing healthcare services. METHODS: An online cross-sectional survey was conducted among patients with IMDs who were present for a follow-up at our clinic to address their problems during pandemic period. Our clinic's Instagram and Facebook accounts were used to invite the participants. Three reminders were given between May 1, 2020, and May 30, 2020. Survey questions were analyzed using descriptive statics. RESULTS: A total of 213 patients completed our survey. Incomplete surveys were excluded, and 175 questionnaires were evaluated. Most of patients had a special diet, and 51% of them had some difficulty with their diet. The reported rate of using a special treatment was 38%, and most of these patients (91%) had no problem receiving these special therapies during this time. Parents who were wearing masks while caring for their child were very few (17%), but a vast majority of parents (73.7%) had high handwashing rates. None of the patients had a SARS-COV2 infection until this paper was written. CONCLUSION: This is the first study that aims to determine the problems faced by patients with IMD during the COVID-19 period. Considering that the pandemic will not immediately pass, recognizing the problems faced by patients with chronic diseases and developing solutions would help these patients avoid long-term damage.


Assuntos
COVID-19/epidemiologia , Doenças Metabólicas/fisiopatologia , Pais/educação , Pais/psicologia , SARS-CoV-2/isolamento & purificação , COVID-19/virologia , Criança , Estudos Transversais , Feminino , Seguimentos , Humanos , Masculino , Doenças Metabólicas/genética , Doenças Metabólicas/prevenção & controle , Doenças Metabólicas/psicologia , Sistemas On-Line , Inquéritos e Questionários , Telemedicina , Turquia/epidemiologia
6.
Int J Environ Res Public Health ; 17(11)2020 06 10.
Artigo em Inglês | MEDLINE | ID: covidwho-622436

RESUMO

The lifestyle adopted by most people in Western societies has an important impact on the propensity to metabolic disorders (e.g., diabetes, cancer, cardiovascular disease, neurodegenerative diseases). This is often accompanied by chronic low-grade inflammation, driven by the activation of various molecular pathways such as STAT3 (signal transducer and activator of transcription 3), IKK (IκB kinase), MMP9 (matrix metallopeptidase 9), MAPK (mitogen-activated protein kinases), COX2 (cyclooxigenase 2), and NF-Kß (nuclear factor kappa-light-chain-enhancer of activated B cells). Multiple intervention studies have demonstrated that lifestyle changes can lead to reduced inflammation and improved health. This can be linked to the concept of real-life risk simulation, since humans are continuously exposed to dietary factors in small doses and complex combinations (e.g., polyphenols, fibers, polyunsaturated fatty acids, etc.). Inflammation biomarkers improve in patients who consume a certain amount of fiber per day; some even losing weight. Fasting in combination with calorie restriction modulates molecular mechanisms such as m-TOR, FOXO, NRF2, AMPK, and sirtuins, ultimately leads to significantly reduced inflammatory marker levels, as well as improved metabolic markers. Moving toward healthier dietary habits at the individual level and in publicly-funded institutions, such as schools or hospitals, could help improving public health, reducing healthcare costs and improving community resilience to epidemics (such as COVID-19), which predominantly affects individuals with metabolic diseases.


Assuntos
Betacoronavirus/imunologia , Infecções por Coronavirus/imunologia , Dieta , Inflamação/imunologia , Doenças Metabólicas/imunologia , Pneumonia Viral/imunologia , Comportamento de Redução do Risco , COVID-19 , Infecções por Coronavirus/dietoterapia , Infecções por Coronavirus/prevenção & controle , Humanos , Inflamação/dietoterapia , Inflamação/prevenção & controle , Doenças Metabólicas/dietoterapia , Doenças Metabólicas/prevenção & controle , Pandemias/prevenção & controle , Pneumonia Viral/dietoterapia , Pneumonia Viral/prevenção & controle , Prevenção Primária , SARS-CoV-2
7.
Cell ; 181(6): 1189-1193, 2020 06 11.
Artigo em Inglês | MEDLINE | ID: covidwho-720440
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA